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Abstract
We study information theoretic methods for ranking biomarkers. In clinical trials
there are two, closely related, types of biomarkers: predictive and prognostic, and
disentangling them is a key challenge. Our first step is to phrase biomarker ranking
in terms of optimizing an information theoretic quantity. This formalization of the
problem will enable us to derive rankings of predictive/prognostic biomarkers, by
estimating different, high dimensional, conditional mutual information terms. To
estimate these terms, we suggest efficient low dimensional approximations, and we
derive an empirical Bayes estimator, which is suitable for small or sparse datasets.
Finally, we introduce a new visualisation tool that captures the prognostic and the
predictive strength of a set of biomarkers. We believe this representation will prove
to be a powerful tool in biomarker discovery.
1 Introduction
We present an information theoretic approach to disentangle predictive and prognostic biomarkers. In
clinical trials, a prognostic biomarker is a clinical or biological characteristic that provides information
on the likely outcome irrespective of the treatment. On the other hand a predictive biomarker, is a
clinical or biological characteristic that provides information on the likely benefit from treatment. One
of the key challenges in personalised medicine is to discover predictive biomarkers which will guide
the analysis for tailored therapies, while discovering prognostic biomarkers is crucial for general
patient care [13]. We should clarify that our work focuses on hypothesis generation (exploratory
analysis), instead of hypothesis testing (confirmatory analysis) [4].
In our work we will focus on a clinical dataset D = {yi,xi, ti}ni=1, where, y is a realization of
a binary target variable Y, t is a realization of binary treatment indicator T (i.e. T = 1 if patient
received experimental treatment, 0 otherwise), and x is a p-dimensional realization of the feature
vector X, which describes the joint random variable of the p categorical features (or biomarkers). To
make the distinction between prognostic and predictive biomarkers more formal we will follow a
strategy introduced by various previous works [6, 8]. Let us assume that the true underlying model is
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the following logistic regression with up to second order interaction terms:
logitP (y = 1|t,x) = α+
p∑
i=1
βixi +
p∑
i,j=1
βi,jxixj + γt+
 p∑
i=1
δixi +
p∑
i,j=1
δi,jxixj
 t.
Covariates with non-zero β coefficients are prognostic, while the ones with non-zero δ coefficients are
predictive. Our work proposes an information theoretic framework for deriving two different rankings
of the biomarkers, one that captures their prognostic strength, and one that captures their predictive
strength. On top of that, we introduce a visualisation tool that captures both the prognosticness and
the predictiveness of a set of biomarkers. This tool enables us to identify potentially undiscovered
biomarkers, worthy of further investigation.
2 Background on Biomarker Ranking
This section connects the problem of biomarker discovery, in context of the machine learning problem
of feature selection and the clinical trials problem of subgroup identification.
2.1 Prognostic Biomarker Discovery and Feature Selection
We now demonstrate that the problem of selecting prognostic biomarkers is equivalent to feature
selection using a supervised dataset {yi,xi}ni=1. There are many different methods for feature
selection, but we will focus on information theoretic approaches, where, firstly we rank the features
and then we select the top-k ones that contain most of the useful information. The underlying
objective function is to find the smallest feature set X∗ that maximizes I(X∗;Y ), or in other words
that the shared information between X∗ and Y is maximized:
X∗ = arg max
Xθ∈X
I(Xθ;Y ).
Brown et al. [2] derived a greedy optimization process which assesses features based on a simple
scoring criterion on the utility of including a feature. At each step we select the feature Xk that
maximizes the conditional mutual information (CMI): JCMI(Xk) = Iˆ(Xk;Y |Xθ), whereXθ is the
set of the features already selected. As the number of selected features grows, the dimension of Xθ
also grows, and this makes our estimates less reliable. To overcome this problem low order criteria
have been derived. For example, by ranking the features independently on their mutual information
with the class, we derive a ranking that takes into account the relevancy with the class label. Choosing
the features according to this ranking corresponds to the Mutual Information Maximization (MIM)
criterion; where the score of each feature Xk is given by: JMIM(Xk) = I(Xk;Y ). This approach
does not take into account the redundancy between the features. By using more advanced techniques
[11], we can take into account both the relevancy and the redundancy between the features themselves,
without having to compute very high dimensional distributions. Brown et al. [2] showed that a criterion
that controls relevancy, redundancy, conditional redundancy and provides a very good tradeoff in
terms of accuracy, stability and flexibility is the Joint Mutual Information (JMI) criterion [15]:
J JMI(Xk) =
∑
Xj∈Xθ Iˆ(Xk;Y |Xj). Through heuristic, this guarantees to increase the likelihood at
each step.
While the above framework has been suggested for supervised scenarios, our aim is to explore how
it can been extended to be useful in clinical trial scenarios, i.e. D. The extra treatment variable T
provides interesting dynamics, but before showing our suggested extension, we will briefly present
the literature on predictive biomarkers and subgroup identification.
2.2 Predictive Biomarker Discovery and Subgroup Identification
The problem of deriving predictive biomarkers is closely related to the problem of subgroup identifi-
cation [4]. In clinical trials, patient populations cannot be considered homogeneous, and thus the
effect of treatment will vary across different subgroups of the population. Exploring the heterogeneity
of subject responses to treatment is very critical for drug development, which is underlined by a
draft Food and Drug Administration guidance [13]. As a result consideration of patient subgroups
is necessary in multiple stages of trial development. Berry [1] gives the following definition: sub-
grouping is a partition of the set of all patients into disjoint subsets or subgroups and it is usually
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determined by a small number of measurable covariates, which are the predictive biomarkers. In the
traditional subgroup identification problem the set of predictive biomarkers is relatively small, i.e.
2-3 biomarkers [9].
In the literature there are many different methods for subgroup identification. A popular one is
recursive partitioning of the covariate space, using criteria that capture the interaction between T and
Y [9, 10, 14]. Another solution builds upon the counterfactual modelling idea: firstly by deriving a
new variable for each patient that captures the treatment effect and then using this variable to select or
rank the covariates. For example, Foster et al. [6] can be seen as exploring the covariate space which
maximizes the odds-ratio between T and Y . In the following section, we will show that starting from
a natural objective function, we can derive predictive biomarkers by exploring areas that maximize
the mutual information between T and Y .
3 An Information Theoretic View on Biomarker Ranking
Our work extends the feature ranking framework from supervised to clinical trial data. The treatment
variable T provides extra useful information, and a natural way to capture this is by the following
criterion: to maximize the shared mutual information between the target Y and the joint random
variable of the treatment T and the optimal feature set X∗, or in information theoretic notation:
X∗ = argmax I(XθT ;Y ). By using the chain rule [3], these objective can be decomposed as
follows in the following way:
X∗ = arg max
Xθ∈X
I(XθT ;Y ) = arg max
Xθ∈X
(
I(Xθ;Y )︸ ︷︷ ︸
Prognostic term
+ I(T ;Y |Xθ)︸ ︷︷ ︸
Predictive term
)
The first term, captures the features with prognostic power, while the second captures the features with
predictive power. By optimizing these two terms independently we can derive two different objectives
for the two different features set: X∗Prog = arg max
Xθ∈X
I(Xθ;Y ) and X∗Pred = arg max
Xθ∈X
I(T ;Y |Xθ).
Similar to [2], to optimize these two objectives, we can derive a greedy optimization process, where
are each step we select the feature Xk that maximizes the following terms:
JProg(Xk) = I(Xk;Y |XProg), JPred(Xk) = I(T ;Y |XkXPred).
whereXProg are the features already been ranked as prognostic, whileXPred as predictive. As the
number of selected features grows, the dimension ofXProg andXPred also grows, and this makes
the estimates less reliable. To overcome this issue, we derive low-order approximations, such as the
one presented in Section 2.1.
3.1 Lower-order approximations
With the following theorem we present our main contribution – lower order approximations of
JProg(Xk) and JPred(Xk):
Theorem 1. The first two order approximations for deriving Prog. and Pred. rankings are given by:
J1
st
Prog(Xk) = I(Xk;Y ),
J2
nd
Prog(Xk) =
∑
Xj∈XProg
I(Xk;Y |Xj),
J1
st
Pred(Xk) = I(T ;Y |Xk).
J2
nd
Pred(Xk) =
∑
Xj∈XPred
I(T ;Y |XkXj).
Proof sketches: For prognostic, the proof is identical to [2], while for the predictive we can prove
these approximations by combining the results of Brown et al. [2] with the chain rule [3].
For example, by making assumptions similar to the ones of MIM, we can derive the 1st-order criteria
for deriving prognostic and predictive rankings respectively. These criteria do not take into account
interactions between features, and as a result fail to capture the redundancy. To overcome this
limitation so we can use higher order criteria, such as JMI, which explores 2nd-order interaction
terms between features.
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3.2 Estimating Conditional Mutual Information Through an Empirical Bayes Approach
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Figure 1: MSE between maximum
likelihood and empirical Bayes es-
timator for conditional mutual in-
formation I(T ;Y |X) = 0 with
|T | = |Y| = 2 and |X | = 25.
In order to derive the above rankings we need to estimate condi-
tional mutual information terms. In our work we will focus on
categorical data, and we derive an efficient way for estimating
these terms through an empirical Bayes procedure. Due to
space limitations we omit the technical details, but our analysis
extends a work on entropy estimation. Hausser and Strimmer
[7] suggested an entropy estimator that employs James-Stein-
type shrinkage at the level of cell frequencies. Building upon
this, we derived an estimator for the conditional mutual infor-
mation. Our proposed estimator achieves smaller mean squared
error than maximum-likelihood, especially in “small n, large
p” scenarios – which are common in micro-array data. For
example, Figure 1 compares the performance of the maximum
likelihood estimator against our proposed empirical bayes ap-
proach, and as we observe our proposed estimator converges
much faster.
4 Predictive–Prognostic (PP) Graphs
We now present a visualisation tool that captures both the prognostic and the predictive power of a set
of biomarkers (PP-graphs). We believe that this representation will provide useful information over
both the prognostic and predictive power of each biomarker, and it will be helpful for controlling
false discoveries in clinical trials. For example, in subgroup-identification (Section 2.2), we define
interesting subgroupings by using predictive biomarkers. Many methods, such as the counterfactual
modelling, i.e. Virtual-twins suggested by [6], derive as predictive, biomarkers that are strongly
prognostic. Using a PP-graph we get more insight over the prognostic and predictive power of each
biomarker and this may help in eliminating these type of errors.
Now we will show these graphs through a motivating example. We will use the same data generation
model as in [6]. Let us assume that we simulate randomized trials with 1000 patients, and the Xs are
generated as independent Xj ∼ N(0, 1), j = 1...15. We consider logit models for data generation
logitP (y = 1|t,x) = −1+0.5x1+0.5x2−0.5x7+0.5x2x7+0.1t+1.5tI(x1 > 0∩x2 < 0∩x3 > 0).
Thus, the patients with (x1 > 0 ∩ x2 < 0 ∩ x3 > 0) will have an enhanced treatment effect. As a
result the three variables, X1, X2 and X3, are the predictive biomarkers. Furthermore, X1, X2 and
X7 are the three prognostic biomarkers and the other nine biomarkers are irrelevant.
Figure 2 shows three PP-graphs. In the x-axis we have the normalised score of each biomarker
derived by a prognostic ranking. We normalised scores to take values from [0, 1], where 1 is the score
for the most-prognostic biomarker. In the y-axis we have the normalised scores for the predictive
ranking. The red area (vertical shaded region) represents the top-k prognostic-biomarkers, while the
green (horizontal shaded region) the top-k predictive, for these specific PP-graphs we used k = 3,
which corresponds to the score cut-off value of (p− k)/p = (15− 3)/15 = 0.80. The intersection
of these two areas – orange area (top right shaded corner)– should contain the biomarkers that are
both prognostic and predictive. We plot the average predictive/prognostic rankings over 100 sample
datasets, using Virtual-twins [6] and our two approaches suggested in Theorem 1. For estimating
mutual information, the features were discretized in 4 equal width bins. As we observe, Virtual-twins
[6], tends to push a prognostic biomarker (i.e. X7) into the predictive area –false positive. The
1st-order approach classifies X1 only as prognostic and not as predictive –false negative. While, our
2nd-order criterion distinguishes perfectly between predictive and prognostic.
5 Conclusions and Future Work
In this work we focused on disentangling rankings of the biomarkers that quantify their predictive
and their prognostic power. We presented an information-theoretic approach, where we started from
a clearly specified objective function and we suggested lower-order approximations. Furthermore,
we suggested an efficient estimator for these approximations, by using an empirical Bayes approach
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(a) Virtual-twins.
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(b) Our 1st-order approach.
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(c) Our 2nd-order approach.
Figure 2: P-P graphs when: X1, X2 andX3 are truly predictive, X1, X2 andX7 are truly prognostic,
and the rest nine biomarkers are irrelevant. Note that our our 2nd-order approximation distinguishes
perfectly between predictive and prognostic.
to estimate conditional mutual information. Lastly, we introduced a new graphical representation
that captures the dynamics of biomarker ranking. For future work we are planning to apply our
methodologies in discovering cardiovascular events in patients undergoing hemodialysis [5]. This
study contains numerical and categorical covariates. Since discretizing the numerical features it may
be a suboptimal solution, we should explore ways of handling them directly. One potential approach
is by using the maximal information coefficient [12]. Another interesting direction is to improve
the interpretability of the PP-graphs. For example, in the 1st-order approach, instead of plotting the
ranking score of each biomarker, we can plot a p-value, derived from a univariate testing of whether
the biomarker is predictive or prognostic.
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